Home > Insider Trading > Filing (0001144204-11-041904)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1137883	Brainstorm Cell Therapeutics Inc	BCLI	Biological Products, (No Disgnostic Substances) (2836)	912061050

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1305117	S Malcolm Taub	C/O Brainstorm Cell Therapeutics, Inc. 605 Third Avenue, 34Th Floor New York NY 10158		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2010-05-06	100,000	$0.00	100,000	No	4	A	Direct
Common Stock	Acquisiton	2011-06-27	108,333	$0.00	208,333	No	4	A	Direct
Common Stock	Acquisiton	2011-06-27	130,000	$0.00	338,333	No	4	A	Direct
Common Stock	Disposition	2011-07-08	100,000	$0.46	238,333	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	A	Direct
No	4	A	Direct
No	4	S	Direct

Footnotes

Shares acquired are shares of restricted stock awarded pursuant to the Brainstorm Cell Therapeutics 2005 Stock Option and Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on July 27, 2011 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.
Shares acquired are shares of restricted stock automatically awarded on June 27, 2011 pursuant to the Brainstorm Cell Therapeutics Inc. Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on July 27, 2011 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.
The transaction was executed in multiple trades at prices ranging from $0.4505 to $0.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.